Laboratory News and Research

RSS

New approach can design antibiotics that kill even 'superbugs'

The world needs new antibiotics to overcome the ever increasing resistance of disease-causing bacteria - but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that kill even "superbugs" but spare the delicate sensory cells of the inner ear.

12 Jun 2012

Scientists establish link between autoimmune diseases and nanoparticles

New groundbreaking research by scientists at Trinity College Dublin has found that exposure to nanoparticles can have a serious impact on health, linking it to rheumatoid arthritis and the development of other serious autoimmune diseases.

12 Jun 2012

Trudeau Institute to receive sub-contract for translational research grant from NIH

The Trudeau Institute has announced it is the recipient of a sub-contract for a translational research grant from the National Institutes of Health.

12 Jun 2012

CRT, BioInvent partner to identify new therapeutic antibodies in oncology

BioInvent International AB and Cancer Research Technology Ltd (CRT), the commercial arm of Cancer Research UK, announced today that they have entered a collaboration with Queen Mary, University of London, to identify new therapeutic antibodies in oncology.

12 Jun 2012

Enzo Biochem third quarter total revenue increases 4% to $26 million

Enzo Biochem, Inc. today reported results for the fiscal third quarter ended April 30, 2012.

12 Jun 2012

BioMed Realty enters definitive agreement to acquire Granta Park

BioMed Realty Trust, Inc. today announced that it has entered into a definitive agreement to acquire Granta Park, comprising eleven laboratory and office buildings and a total of approximately 472,200 square feet of space, as well as approximately 138,400 square feet of development and expansion rights, in Cambridge, United Kingdom. The purchase price for the property is 126.8 million pounds, or approximately $196.0 million, excluding transaction costs.

11 Jun 2012

Lack of sleep a hypertension warning sign

Individuals who sleep for 5 hours or less each night are at increased risk for developing hypertension, suggest study findings.

11 Jun 2012

New liquid stable homocysteine kit from Randox

The new liquid stable homocysteine kit from Randox provides a convenient and accurate method for the determination of homocysteine in human serum and plasma. Homocysteine is a potential indicator of a number of disease markers and should therefore be an integral part of a laboratory’s testing menu.

From Randox Laboratories Ltd. 11 Jun 2012

Powerful new tools can study glycans’ function

Scientists at The Scripps Research Institute have developed chemical compounds that can make key modifications to common sugar molecules ("glycans"), which are found on the surface of all cells in our body. The new study presents powerful new tools for studying these molecules' function, for example in cell signaling and immunity, and for investigating new treatments for chronic inflammation, autoimmune diseases, cancer metastasis, and related conditions.

11 Jun 2012

MRI scans reveal how sleep deprivation impairs brain regions associated with food processing

MRI scans from a study being presented today at SLEEP 2012 reveal how sleep deprivation impairs the higher-order regions in the human brain where food choices are made, possibly helping explain the link between sleep loss and obesity that previous research has uncovered.

11 Jun 2012

Sleep loss markedly exaggerates emotional reactivity in people with anxiety disorders

New research shows that sleep loss markedly exaggerates the degree to which we anticipate impending emotional events, particularly among highly anxious people, who are especially vulnerable.

11 Jun 2012

First study to use simulated driving tests on medical staff returning home after night shift

The drowsiness experienced by medical staff who have been on night duty can make their driving dangerous, French researchers have found.

11 Jun 2012

Incyte, Lilly announce 12-week results from baricitinib Phase IIb study on RA

Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis.

11 Jun 2012

Effective ways of detecting onset of kidney disease

Research led by an Arizona State University biomedical engineer and physicist to find more effective ways of detecting the onset of kidney disease is getting support from the National Institutes of Health.

8 Jun 2012

Project aims to reduce transmission of infectious diseases on aircraft

A new study is expected to provide the first detailed information on how infectious diseases may be transmitted aboard commercial airliners. Sponsored by aircraft manufacturer Boeing, the research will document patterns of passenger movement inside aircraft cabins and inventory the microbes present in cabin air and on surfaces such as tray tables and lavatory fixtures.

8 Jun 2012

Study: HIV superinfection may be more common than previously believed

Human immunodeficiency virus (HIV) superinfection may be as common as initial HIV infection and is not limited to high risk-populations, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and the National Institute of Allergy and Infectious Diseases.

8 Jun 2012

Study packs powerful one-two punch in the fight against heart failure

A new study in the journal Circulation packs a powerful one-two punch in the fight against heart failure. The leading blow: Identification of a unique alliance of proteins that plays a major role in the development of the disease. The second but equally powerful hit: Drugs that interfere with this axis already exist.

8 Jun 2012

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

8 Jun 2012

Tp53 genetic mutation may play an important role in prostate cancer

A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.

8 Jun 2012

Strand, Trovagene enter MOU to license and validate HPV assay technology

Trovagene, Inc., a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation.

8 Jun 2012